0.63
0.33%
-0.0021
After Hours:
.634
0.004
+0.63%
Quoin Pharmaceuticals Ltd ADR stock is currently priced at $0.63, with a 24-hour trading volume of 239.67K.
It has seen a -0.33% decreased in the last 24 hours and a -25.97% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.644 pivot point. If it approaches the $0.6181 support level, significant changes may occur.
Previous Close:
$0.6321
Open:
$0.668
24h Volume:
239.67K
Market Cap:
$2.32M
Revenue:
-
Net Income/Loss:
$-8.69M
P/E Ratio:
-0.0137
EPS:
-45.9343
Net Cash Flow:
$-7.86M
1W Performance:
-12.50%
1M Performance:
-25.97%
6M Performance:
-87.04%
1Y Performance:
+23.80%
Quoin Pharmaceuticals Ltd ADR Stock (QNRX) Company Profile
Name
Quoin Pharmaceuticals Ltd ADR
Sector
Industry
Phone
703-980-4182
Address
42127 Pleasant Forest Court, Ashburn
Quoin Pharmaceuticals Ltd ADR Stock (QNRX) Latest News
Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know
Benzinga
Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results
GlobeNewswire Inc.
Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET
GlobeNewswire Inc.
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
Benzinga
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Nasdaq Down 250 Points; ISM Services PMI Falls In February
Benzinga
Quoin Pharmaceuticals Ltd ADR Stock (QNRX) Financials Data
Quoin Pharmaceuticals Ltd ADR (QNRX) Net Income 2024
QNRX net income (TTM) was -$8.69 million for the quarter ending December 31, 2023, a +7.41% increase year-over-year.
Quoin Pharmaceuticals Ltd ADR (QNRX) Cash Flow 2024
QNRX recorded a free cash flow (TTM) of -$7.86 million for the quarter ending December 31, 2023, a +9.92% increase year-over-year.
Quoin Pharmaceuticals Ltd ADR (QNRX) Earnings per Share 2024
QNRX earnings per share (TTM) was -$10.24 for the quarter ending December 31, 2023, a +87.99% growth year-over-year.
About Quoin Pharmaceuticals Ltd ADR
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia.
Cap:
|
Volume (24h):